logo
Kennedy's firing of U.S. immunization committee is worrisome, Canadian scientists say

Kennedy's firing of U.S. immunization committee is worrisome, Canadian scientists say

Globe and Mail11-06-2025
Canadian doctors and scientists say Robert F. Kennedy Jr.'s firing of an immunization advisory committee south of the border is worrisome.
On Monday, the U.S. health and human services secretary – a longtime anti-vaccine advocate – said he will appoint new members to the scientific group that advises the Centers for Disease Control and Prevention about vaccination.
Angela Rasmussen, a virologist at the University of Saskatchewan, said Tuesday that the move will foster more false anti-vaccine beliefs, not only in the U.S. but also in Canada.
'It creates a culture in which anti-vaxx beliefs are more accepted and challenged a lot less. And also it creates an environment where there's an alternative to an evidence-based recommendation framework,' she said.
Opinion: The measles outbreak shows why we need a vaccine registry
Even though Kennedy's new appointments will make vaccine recommendations specific to the United States, any disinformation could also feed vaccine hesitancy among Canadians, Rasmussen said.
'We have a lot of the same anti-vaxx sentiment up here. Certainly this will at the very least empower [that],' she said.
Rasmussen said current measles outbreaks in both countries show the consequences of disinformation that leads to parents not immunizing their children against preventable diseases.
She said Canada could also experience some fallout if the new committee pulls back vaccination recommendations, because manufacturers may cut back on production and that could lead to shortages.
'There's a lot of potential for really, really damaging vaccine access throughout the U.S. and potentially around the world because the U.S. market has a big impact on what vaccine manufacturers are actually going to make and manufacture,' she said.
'There's so many ways that this can end up really badly for vaccination in general. And it really causes me a lot of concern.'
Rasmussen said the firing of the advisory committee members is just the latest in a series of anti-public health actions Kennedy has taken.
'It's a death by a thousand cuts,' said Rasmussen, who is American and moved to Canada during the pandemic to work at the University of Saskatchewan's Vaccine and Infectious Disease Organization.
Ontario baby's measles-related death highlights that vaccination is critical, health experts say
U.S. President Donald Trump's administration has already cut billions of dollars in research grants at the National Institutes of Health.
In May, the administration cancelled a contract with mRNA vaccine manufacturer Moderna to develop a vaccine against potential pandemic influenza viruses, including H5N1 avian flu.
'It just seems that there is a top-down approach that views mRNA vaccines in particular – vaccination in general, but mRNA vaccines in particular – with distrust and is trying to dismantle that particular avenue of medical research,' said Dr. Jesse Papenburg, a pediatric infectious diseases specialist at Montreal Children's Hospital.
Papenburg, who is a member of Canada's National Advisory Committee on Immunization but was not speaking on its behalf, said although the Moderna contract cancellation and the firing of the U.S. vaccine advisory committee members are two separate actions, they're both concerning as Canada tries to prepare for potential human-to-human transmission of H5N1.
'Both are potentially very dangerous when it comes to America's and the world's ability to respond to emerging infectious diseases for which vaccines could be a useful medical countermeasure,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape
Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time29 minutes ago

  • Globe and Mail

Essential Thrombocythemia Pipeline Outlook Report 2025: Key 6+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, 'Essential Thrombocythemia Pipeline Insight 2025' report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Essential Thrombocythemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Essential Thrombocythemia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Essential Thrombocythemia Pipeline Outlook Report In August 2025:- Icahn School of Medicine at Mount Sinai conducted a phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary Essential Thrombocythemia (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). DelveInsight's Essential Thrombocythemia pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Essential Thrombocythemia treatment. The leading Essential Thrombocythemia Companies such as PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Promising Essential Thrombocythemia Pipeline Therapies such as Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Discover how the Essential Thrombocythemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Essential Thrombocythemia Clinical Trials and Studies Essential Thrombocythemia Emerging Drugs Profile Ropeginterferon alfa-2b: PharmaEssentia Ropeginterferon alfa-2b is a novel, long-acting, mono-pegylated proline interferon (ATC L03AB15). Its pharmacokinetic properties offer a new level of tolerability. Ropeginterferon alfa-2b is designed to be self-administered subcutaneously with a pen once every two weeks, or monthly during long-term maintenance. This treatment schedule is expected to lead to overall better safety, tolerability and adherence compared to conventional pegylated interferons. PharmaEssentia Corporation is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of ET. The Phase III multi-site, open-label, randomized, active-controlled study will compare the efficacy, safety, and tolerability and pharmacokinetics of P1101 as second line therapy for ET as compared with anagrelide, a commonly used oral platelet-reduction therapy. IMG-7289: Imago Biosciences IMG-7289 (Bomedemstat) is an orally available small molecule, discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells, particularly neoplastic bone marrow cells. In non-clinical studies, bomedemstat demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other therapeutic agents. The drug is being evaluated in Phase II clinical trial to treat patients with Essential thrombocythaemia, Essential Thrombocythemia, and Polycythaemia Vera. The Drug has been granted orphan and fast track designation from US FDA. The Essential Thrombocythemia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Essential Thrombocythemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Thrombocythemia Treatment. Essential Thrombocythemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Essential Thrombocythemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Thrombocythemia market. Get a detailed analysis of the latest innovations in the Essential Thrombocythemia pipeline. Explore DelveInsight's expert-driven report today! @ Essential Thrombocythemia Unmet Needs Essential Thrombocythemia Companies PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Essential Thrombocythemia Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Download DelveInsight's latest report to gain strategic insights into upcoming Essential Thrombocythemia Therapies and key Developments @ Essential Thrombocythemia Market Drivers and Barriers, and Future Perspectives Scope of the Essential Thrombocythemia Pipeline Report Coverage- Global Essential Thrombocythemia Companies- PharmaEssentia, Imago BioSciences, Novartis, Constellation Pharmaceuticals and others. Essential Thrombocythemia Pipeline Therapies- Anagrelide, Hydroxyurea, IMG-7289, Bomedemstat, Busulfan, Thromboreductin, Ropeginterferon alfa-2b-njft (P1101) and others. Essential Thrombocythemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Essential Thrombocythemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Essential Thrombocythemia drug development? Find out in DelveInsight's exclusive Essential Thrombocythemia Pipeline Report—access it now! @ Essential Thrombocythemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Essential Thrombocythemia: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Ropeginterferon alfa-2b: PharmaEssentia Mid Stage Products (Phase II) IMG-7289: Imago Biosciences Early stage products (Phase I/II) Drug Name: Company Name Inactive Products Essential Thrombocythemia Key Companies Essential Thrombocythemia Key Products Essential Thrombocythemia- Unmet Needs Essential Thrombocythemia- Market Drivers and Barriers Essential Thrombocythemia- Future Perspectives and Conclusion Essential Thrombocythemia Analyst Views Essential Thrombocythemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Merit expands skin-care offering with first facial cleanser
Merit expands skin-care offering with first facial cleanser

National Post

timean hour ago

  • National Post

Merit expands skin-care offering with first facial cleanser

Article content The news: Merit launches first face cleanser. Article content What you should know: Merit has expanded its Great Skin collection with its first facial cleanser. Dubbed the Great Skin Double Cleanse, the bi-phase formula features a liquid-to-foam texture. Article content Article content 'Great Skin Double Cleanse is a prime example of the Merit philosophy on skin care — that skin care can be work, but having Great Skin doesn't have to be,' says Aila Morin, chief marketing officer (and Canadian) at Merit. Article content 'It's a multi-tasking formula that combines the power of a makeup remover and a cleanser to remove makeup and SPF, with the added benefit of gentle exfoliation, to leave skin feeling soft and smooth. It takes what is normally a two-step process and simplifies it, without sacrificing on efficacy or results.' Article content Article content 'Cleanser is a product that often gets overlooked, but we feel it's the most important step to set you up for great skin, so it's always been on our road map,' she notes. Article content 'When we launched our first skin-care product, Great Skin Serum, in 2021, double cleansing was the norm in skin care. As a brand built on simplifying routines, that multi-step process didn't feel true to us — so we took our time to develop a formula that actually made cleansing easier.' Article content The bi-phase product features ingredients such as oat-derived surfactants, gluconolactone (a polyhydroxy acid), plant humectants, and a lightweight emollient to gently cleanse, exfoliate and soothe skin. Article content With products like the brand's fan-favourite Minimalist Perfecting Complexion Stick (so good!), Flush Balm blush and awesome beauty bundles already among many beauty fans' favourites, we won't be surprised to see this new cleanser finding fast fans. Article content

Hazy holiday: Air quality drops as wildfire smoke blankets southwestern Ontario
Hazy holiday: Air quality drops as wildfire smoke blankets southwestern Ontario

CBC

timean hour ago

  • CBC

Hazy holiday: Air quality drops as wildfire smoke blankets southwestern Ontario

Environment Canada has issued special air quality statements for southwestern Ontario as prairie wildfire smoke sits over swaths of the province. People in the Windsor, Chatham, and Sarnia regions can expect poor air quality and reduced visibility, Environment Canada said Monday morning. "The wildfire smoke may persist into tonight and possibly Tuesday before finally easing." Detroit and Toronto were among the top ten most polluted major cities in the world on Monday afternoon, according to a ranking by Swiss company IQAir. The CBC News Climate Dashboard also showed Windsor and other southwestern Ontario cities had some of the worst air quality in the country. Environment Canada warned of potential health effects, including "mild and common symptoms such as eye, nose and throat irritation, headaches or a mild cough." Wheezing, chest pains, or severe cough are less common but more serious symptoms. Older people, young kids, people with chronic conditions, pregnant people, and those who work outside are at higher risk, Environment Canada said. "If you think you are having a medical emergency, seek immediate medical assistance." The federal weather authority also urged people to limit time outside and consider rescheduling outdoor activities, adding that windows and doors should be kept closed as much as possible. "If you must spend time outdoors, a well-constructed, well-fitting and properly worn respirator type mask (such as a NIOSH-certified N95 or equivalent respirator) can reduce your exposure to the fine particles in the smoke," Environment Canada said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store